`
`
`EXHIBIT 31
`
`REDACTED IN ITS ENTIRETY
`
`REDACTED IN ITS ENTIRETY
`
`EXHIBIT 31
`
`

`

`
`
`
`EXHIBIT 32
`
`REDACTED IN ITS ENTIRETY
`
`REDACTED IN ITS ENTIRETY
`
`EXHIBIT 32
`
`

`

`
`
`
`EXHIBIT 33
`
`REDACTED IN ITS ENTIRETY
`
`REDACTED IN ITS ENTIRETY
`
`EXHIBIT 33
`
`

`

`
`
`
`EXHIBIT 34
`
`REDACTED IN ITS ENTIRETY
`
`REDACTED IN ITS ENTIRETY
`
`EXHIBIT 34
`
`

`

`
`
`
`EXHIBIT 35
`
`REDACTED IN ITS ENTIRETY
`
`REDACTED IN ITS ENTIRETY
`
`EXHIBIT 35
`
`

`

`EXHIBIT 36
`
`

`

`lllllllllllllllllllllllllllllllllllllllllll||||||||l|1||1||
`USOO8309087B2
`
`(121 United States Patent
`Hellmann
`
`(10) Patent No.:
`(45) Date of Patent:
`
`US 8,309,087 B2
`Nov. 13, 2012
`
`(S4) TREATMENT \VlTH ANTI-ERBBZ
`AN “BODIES
`
`(75)
`
`Inventor.
`
`SusanD.llellmann.S:111Carlux,CA
`(US)
`
`(73) Assignee: Generitecli, lnc., Soulh San Francisco.
`CA(US)
`
`( ‘ 1 Notice:
`
`Subject to any disclaimer. the term ofthis
`patent is extended or adjusted under 35
`U.S.C. 154(1)) by 0 clays.
`
`(21) Appl.No.: 13/103399
`
`(22)
`
`Filed:
`
`May 9. 201]
`
`(65)
`
`Prior Publication Data
`US 2011/0250194 A1
`Oct. 13, 2011
`
`Related LLS. Appllcntlon Data
`
`(60) Continuation 111'npplicalion No. 11/969,465. filed on
`Jan. 4. 2008,11011/ abandoned. which is a continuation
`of application No. 10/406325. filed on Apr 4. 2003.
`now abandoned, which is a division of application No.
`09/209023. filed on Dec. 10. 1998. now abandoned.
`
`(60) Provisional application No. 60/069,346. filed on Dec.
`12.1997.
`
`(511
`
`lm.(‘l.
`.161K39/395
`(52) us. (:1.
`
`(2006.01)
`424/1434; 424/1301: 424/133 1;
`424/] 34.1; 424/1351; 424/1361: 424/138J;
`424/141.l;424/'155.l;424/174.1
`Field ofClnIslficatinn Search ............... 424/130 1,
`424/1111,1341.135.1,136.1,1381,14l1,
`424/1411, 143.1, 155.1, 174.1
`Sec application file for complete search history.
`
`(58)
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`4/1977 Davies
`(1- 1988 Frankel et a1.
`6/1990 Bargmann ct a1.
`7/1990 Mendel 501m at 11.
`1 1/1990 Slainon «:1 nl.
`12/1990 Senter ct al.
`21/1991 Armour Ct 81
`12/1992 Frankel et al
`2/1993 Kraus er a1
`3 1994 “new
`111 1994 ( :ipun e1 :11
`I
`l 1994
`\krntllcli cl :11
`.1 1'19."
`1 znncy :1 .11
`ll [9'19
`li1ccnc 1:1 111
`1 I006 Kl'illlfi c1 :11
`< 1000 linens.
`I I 10110 Wcls 1.1111
`l
`l 1906 l ippmnn ml
`I.‘ 19011 King et :11
`'7
`. 199'
`( rirncy c1 .11
`(1 [9‘17 Vilndlcn e1 :11
`‘./' l‘N" (Elven/c e1 :11
`It] 1097 lluil'nnl; k" :11
`I
`[003 tirccnc
`
`2>>>>2>>2>>>>>>>>>>>>>>>
`
`.'11
`
`4.017.471
`4.755.894
`4.935.341
`4.947.533
`4.968.603
`4.975.278
`4.994.558
`5.169.774
`1181.884
`5 288,177
`5 35.9.1146
`5 3107.061)
`5 401.6le
`i 401.7.”
`5.118113%?1
`5.511.151
`3 571.891
`5 “MAXI
`S “(7.4%:
`§ (101. 107
`\'. (1'11 .869
`< (10}. 1'14
`5 (177.171
`< 70711:?
`
`5.720.937
`5.720.954
`5 725,856
`5.726.023
`5.728.687
`5.747.261
`5.770.195
`5.772.097
`5.776.427
`5.783.186
`S 783,404
`S.80l,005
`5.804.396
`5.821.337
`5.824.311
`5 1134.220
`5 837,523
`5 840.525
`5346.5.“
`5.846.749
`5.856.089
`5 856,110
`5.859.106
`5 1169.445
`5.876.712
`5 27mm
`5 «10mm
`
`>>>>>>>>>>>>>>>>>>>>>>>>>>>
`
`2/1')98 Hndziakctnl
`3/1998 Hudziakctal.
`3/1998 Hudziakct .11
`3/1998 (Zliccvcr c1111.
`3/1998 Bisscry
`5-1998 Kingel :11.
`6.1993 Hudzinketal.
`6/1998 lludziaketnl.
`7/1998 Thorpe et n1
`7/1993 Araknvsn et at.
`7/1998 Koslti
`9/1998 Chewcr ct a].
`9/1998 Plowman
`10/1998 Carteretal.
`10-1998 Greene e1 n1.
`11/1998 Vandlen 21:11
`1 1/1998 Greene cl ul
`11/1998 Vandlcn e1 at
`1111998 Chewer et at
`11/1998 Slzmon e! at
`1/1999 Wang er a1
`1/1999 Vandlcn or at
`1/1999 Vandl- e1 .11.
`1/1999 (Iheever et a1.
`3/1999 CIIGWCI’ et al
`L’l999 Huston at al
`1’ 1 99‘) Kisser)!
`(Continuedl
`
`111’
`
`FOREIGN PATENT DOCUMENTS
`(1 599 274 A1
`6/1994
`
`(Continued)
`OTHER PUBLICATIONS
`
`Busclgn. .1. e1 31 . Journal ofClinical Oncology. 14(3): 737-744. Mar
`1996 ‘
`11117111“: A U cf :11 , Cancer 7‘7: 25071-2513. Jun 1996 ‘
`Buzdar. .\.U et 31., J. Clinical Oncology 14: 2000-2011. Jul. [996 "
`Klijn. J. Steroid Biochern. Melee. Biol. 43(1-3): 211-221. 1992.‘
`Witwis. L.M.. ct al. Breast Cancer Research and 't‘retltmrnt. 42: 1-5.
`1997.‘
`"An adjuvnnl Herceptin trials using the wrong drugs?" Scrip
`2493: 21 (1999).
`[ablets" Physicians' Desk Reference
`"Arimidex (mash-0201c)
`(website version ofpmduct information) pp. 1-14. (2003).
`"Aromnsin (excmcsluc ublctn)" Physicim' Desk Reference
`(website version ofpioiluct infatuation) pp 1-9. (2003).
`Anna a 111.. "Clinical Activity in a PM“: lTrinl of HER-Z-Tnmod
`rluMAb 2C4 (pcrtu‘lmnnh) in Patients with Advanced Solid Malig-
`nancics MST)" Proceedings ofllm American Associuion for Cancer
`Research lAhsu'act No. 771). 22:192.(2003).
`
`(Continued)
`Primary Examiner ,- Alana Harris Dent
`Assistant Examiner — Anne Hollertm
`(74) Altar/rev. Age/ii. or 1'1‘1'111—-Diune Marschang: Ginger
`R. Dug/n: Amnld & Porter 1.1.1)
`(57)
`Alls'l‘RAF'l‘
`1111: present
`invcntmn concerns the "eminent 111 disorders
`clulnrclcrixed I?) the mercxpressiun ul‘l-Irhll2. More syn-cili-
`cnlly. the invention ammunis 1111- Iruntnu‘nl 11111111111111 ptlllt‘llN
`suscqilihlc to ur diagnosed wilh cunccr owruxprussing
`11117112 with .1 cumlriuuliun 111';111.11111-l'111|12untihudyslud .1
`clicmnlhempculic 113,011! other 111:111
`1111 zinlhnrcyclinc. cg
`dummhicin 111 epinihicin. 'l he invention further provides 11
`mullmd 111' trailing cancer in :1
`|111111:111 pulicnl comprising
`administering ell'eclivu amounts 111 .111 nuti-l-Zrlilll’ 111111111111)-
`;md .- mnlinpnrlcclunl tn the patient
`)1 ('laims. I Drawing Slit-ct
`
`AMGKAN02977625
`
`

`

`US 8,309,087 B2
` Page 2
`
`424/1301
`
`U.S. PATENT DOCUMFNI‘S
`5.910.486 A
`6/1999 ('uriel cl :1]
`5,922,845 A
`7/1999 Dec 61 :11.
`5.925.519 A
`7/1999 Jensen elul,
`5.939.531 A
`8/1999 Welsetul.
`5.977.322 A
`11/1999 Marks «:1 a].
`5.985.553 A
`11/1999 Kingdul.
`5.994.071 A
`11/1999 Russel :11.
`6.015.567 A
`[/2000 11111121111; 1:1 :0.
`6.028.059 A
`2/2000 Cm‘ieldal.
`6.054.297 A
`4/2000 Canct ctnl.
`6.054.561 A
`4/2000 Ring
`6.123.939 A
`9/2000 Slnwver ct nl.
`6.165.464 A
`12/2000 [[udzink 6111.1.
`6.214.388 131
`4/2001 Benzelal.
`6.214.863 Bl
`4/2001 Dissery
`6267.958 13]
`7/200] Andyaclal.
`6.270.765 Bl
`8/2001 Dco c111,
`6.316.462 Bl
`11/2001 Dishopct a1.
`6.333.348 Bl
`12/2001 Vogcl er 31.
`6.339.142 Bl
`1/2002 aneyel :11.
`6.387.371 Bl
`5/2002 Hudziak 01 :11.
`6.395.712 B1
`5/2002 Hung at 11.
`6.399.063 Bl
`6/2002 11ndzink at .11.
`6.407.213 Bl
`6’2002 Caner at :11.
`6.458.356 Bl
`10’2002 Amknwnetnl.
`6.512.097 Bl
`1/2003 Marks :1 n1.
`6.627.196 Bl
`9/2003 Bmlghman e1 :11.
`6.639.055 31
`10/2003 Carter :1 :11.
`6.685.940 B2
`1120041 Audya ct 31
`6.719.971 Bl
`4/2004 Camera n1.
`6.8m.738 Bl
`10/2004 Caner et :11.
`6.821.515 Bl
`11/2004 ("Island 2191.
`7.041.292 131
`5/2006 Sliwkowflii
`7.000.268 152
`6/2006 Andya el :11.
`7.097.840
`2
`8/2006 Erickson etal.
`20000014326 A1
`8/2001 Andy» ctal
`Kill/0001587 AI
`1/2002 Erick/um et :11
`NIH/0076408 A1
`6/2002 Buchahaum
`2m2’0155527 A1
`10/2002. Sman elal.
`2m3'0103973 A1
`6/2003 Rockwell c131.
`20030108545 A1
`6/2003 Rockwell clal.
`2103101471184 A1
`11/2003 Patch 6 :11.
`2003/0170234 A1
`9/2003 Hclhnnnn
`200350202972 A1
`10/2003 Andya c1 81.
`211140013660 A1
`1/2004 Bissery
`200410037823 A9
`2/2004 Paton et :11.
`2004-0037824 A1
`2/2004 Baugmun et :1.
`200410106161 A1
`6/2004 Busscnmaicrctal.
`200410236078 A1
`11/2004 Curler et 31.
`200410258685 A1
`12/2004 Blunclla cl a1,
`200510002928 Al
`1/2005 Hellmann
`zoos/0203043 A1
`9/2005 Adams at a].
`20050238640 A1
`10/2005 Sliwkowski
`2005'0244417 A1
`11/2005 Ashkeuazi 01 n1,
`20000013819 A1
`“3006 dey
`20060018899 A1
`"2006 Kw d al-
`200610034840 Al
`2/3006 Agus
`2°00 003““ N ”41°“ Adm“ °‘ “'-
`_.
`-
`-
`,-
`zoos/00.3143 A1
`4/2006 Adams at al.
`2006 0083/39 A1
`4/2006 Sllwkowsh
`2006001111523 A1
`4/2006 Andya c. 111.
`20050099201 Al
`5/2006 may“ c. “I,
`20060121044 A1
`6/2006 ““1" ct n1.
`2m6'0165703 ,\|
`7'2006 Allison cl ”1,
`21X16 01988-13 Al
`‘) .7006 Adams :1 n1
`21116 0.101505 Al
`'1 2011(- Sliwkuwski cl :Il
`200“ "3105“ A'
`I) 3006 11""E)‘"“"‘ “‘1 “1
`30"“ 0359/45 "‘1
`'0 300‘! ““53
`70000205395. “I
`l’! 3,0116 Blynm
`21X") 03.75.1116 AI
`13 2001‘ Andy: 1'1 :11
`1007 00.20261 AI
`1 3007 Mitt-10mm 1-1 :11
`7110701))MKlI AI
`.2 .2007
`\sllkcmzi N "I
`2007 00173.18 AI
`3 2007 Mum-1‘s u ,-.|
`sum olx-mss Al
`:4 .mo‘: sniwtuwm
`.)[x;7[)_vu.g<|(. AI
`5 300“ Mass
`3(x17()_'_.‘4_u)1 ,\|
`U 2001 l-ricss cl :11
`.3007 01694.“)
`.-'\I
`1
`“U117 Rely.) c1 nl
`1
`2007 0192419 ,\I
`12 .1007
`llcllmunn
`
`1-3?
`EP
`1P
`JP
`JP
`JP
`JP
`11’
`JP
`JP
`11’
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`WU
`W0
`W0
`W0
`W0
`WO
`\Vf)
`W0
`W0
`W0
`\VO
`W0
`W0
`W0
`W0
`W0
`W0
`
`FOREIGN PATENT DOCUMENTS
`0616 812 Bl
`9/1994
`0 711 565
`8/1998
`3-240-198
`10/1991
`5-117165
`5/1993
`5-170667
`7/1993
`5-213775
`8/1993
`53517084
`12/1993
`95006982 1'32
`1/1995
`7-59588
`3/1995
`2761543 132
`6/1998
`2895105 112
`5/1999
`WO 87107646 A2
`12/1987
`W0 89/06692
`7/1989
`W0 89/10412 A1
`11/1989
`WO 91/02062 A2
`2/1991
`W0 91/05264 A1
`4/1991
`W0 92.10573
`6/1992
`WO 93303741 A1
`3/1993
`W0 93.712220 A1
`6/1993
`W0 93/161115 AZ
`8/1993
`W0 93121232 A1
`10/1993
`W0 93121319 A1
`10/1993
`WO 94100136 A1
`1/1994
`W0 94/223478 A1
`10/1994
`WOW/28127
`12/1994
`WO 95116051
`6/1995
`WO 95/17507
`6/1995
`WO 95528485
`101995
`W0 96-07321 Al
`3/ 1996
`W0 9616673 A1
`6/1996
`W0 96'18409
`6/1996
`W0 96340789 A1
`12/1996
`\VO 97/011271 Al
`1/1997
`W0 97/208515 A1
`6/1997
`W0 97/278118
`8/1997
`WO 97138731 A1
`10/1997
`wn 98/0246] AI
`1/1998
`\VO 9K’l7797 Al
`4/1998
`W0 98/111489 A1
`5/1998
`W0 98513914 Al
`8/1998
`W0 08.115479 A1
`10/1998
`WO 99/24401
`5/1999
`W09W25320
`5/1999
`W0 99.31140 AI
`6/1999
`W0 00.61145 A1
`10/2000
`W0 00/694110 A1
`11/2000
`W0 01/117334 A1
`11/2001
`WO 02055106 A2
`7/2002
`\VO 20075145862 A2
`12/2007
`‘
`_
`__
`,_
`OTHER PUBULAI IONS
`Albancll at al., "Tarzan-numb. nhumnnizcd anti-HERB monoclonal
`antibody.
`for the trcntment 01' breast cancer" Drugs of Today
`35(12);93|-946.(1999).
`Allmncll. 1. :1 111.. New Tleuk in Cancer for the 2131 Century. ed
`1.10mbarr-Bosch. KluwcrAcademjc,200.1.pp.253-268
`Argiris
`and DiGiovanna.
`“Synergistic
`interactions between
`tamoxifen and HERCBPI'IN 1M" Proceedings of the Amaicnn
`aaocwtlon for Cancer Rcscarch (Ahmad #4565) 41.718. (2000).
`A
`.
`~
`.
`,
`,-
`,-
`_:
`.
`.
`.
`.
`,
`.
`.
`Arleaga er a1... p185; abs Slymlmg filflmuu‘prlalm-mrlugul
`Cytotoxic-w 111 Human Breast Carcmomn (.clls: Association
`Betwecnnn ()ncogcnic Roceplor'l'yrosine Kinase and Drug-induced
`DNA kqanir'Cnncchcscnrch 54(14):.17511-3765.11994)
`Ilncuscl“1.,"1)111'clcnlizllimml‘Cllllurcd“unumlhcuxl('anccfl'rlls
`(>\11-5(\5:Im1M(‘15-T) \ssocimcxl Will! 1 ossul'('c11.’~1url§wc“FR-2:
`Ilul Ami-,-
`1“ Molecular (';l|cilmgulc.\m 1161350662 1 Iwm.
`11660501311”"1.1110001111110110” Monuclonnl.~'\nlilxx|iuslolhc 11111-
`.7 \lcu Recuplur Innlncu Iiill'crcnlinlinn "1' Human Ilrmst 1 nnccn
`( c11<"("lm:ur ch1rch‘i‘('1)"75‘10-‘ ‘N'J ( '90,)
`.
`.
`H ‘1'
`.
`'_
`I
`\4 .
`'1'. "' .'. ‘j, ‘
`“
`f
`was pl .Im . mu whn. Ruqxlm 111011.111; Wnlh Monucloml
`\nlihmlics As Anti-('nncu 'l'hcmpy” I‘lnrnmc '1 1Ic1.. 6-1 127~1 54.
`”994'-
`_
`”51501:;1L1111..".\1111111‘I1(2111111ullll/L‘l1.\1l'lll.'\.'10115|1(\lll11h111)'1.\1‘\1)1
`\lnnc am! in ( nmhmminn with ('hcnnlhcmpy Agninul Human
`“was” ‘zuvinnnul chugulfls" l’r-‘vculingsul 1M '1)
`1.1111 \mmul
`\‘1wling1‘1mllxwl "55,-. |).'Ill:ls. ’IX 13:6} (ll/94).
`
`AMGKAN02977626
`
`

`

`US 8,309,087 BZ
`Page 3
`
`Baselgn ct ill . "Antitutnor activity 01‘ paclttaxcl ill combination with
`nnti-growtli Dictor receptor monoclonal antibodies in breast cancer
`xenogmfts" Proceedings of the American Association for Cancer
`Research (Abstract No. 2262) 35380 (Mar. 1994).
`Basclga ct al., “HER2 ()vcrcxprossion and Pnclitmtcl Sensitivity in
`Breast Cancer: therapeutic Implications" Uncology (Supplement
`No.2). 11(3):43—48. (1997).
`8:13er cl al.. “Monmlottal Antibodies Directed Against Growth
`Factor Receptor: Enhance the Efficacy of Chemotherapeutic
`Agents." Annals ot‘Oncology (abstract #010) 5(Suppl. 5) (1994).
`anclga. ct a1, "Antitutnor efiectsofdoxorubicin in combination with
`anti-epidermal growth factor receptor monoclonal antibodies". Jour-
`nal of the National Cancer Instittne 85(16): 1327-1333. (1993).
`Peg-am et al.. "Phase 11 Study of Intravenous Recombinant Human-
`ized Ami-p135 HER-2 Monoclonal AntibodytrhuMAb HER-2) Plus
`(iisplatin in Patients with HER-Z:NF.U ()vcrexpressing Metastatic
`Breast C:iacer” Proceedings of
`the ASCt)—--‘3 [at Annual
`Mccting.(Abstractt1124) [4:106 (1995).
`Vitsltoglou-Numiltos cl 311.. “Clinical predictive value of the in film
`cell line, human xenogriii't. and mouse nllogmtt preclinical cancer
`models" Clinical Cancer Research 90 t):4227-423. (2003).
`Basclga ct 111.. “llERZ Ovct’cxprcssion and Paclitaxcl Sensitivity in
`Breast Cancer: Therapeutic ltrtplications" Oncology (Supplement
`No.2) 11(3): 4348.1Mar. I997).
`Baselgn or 111.. "Monoclonal Antibodies Directed Against Growth
`Factor Rcccplois Enhance the Emcncy ot‘ Cliciitulhcrapcutic
`Agents." Annnls nt‘Oncnlogy (abstract 11010) 5(Suppl .5) (1994).
`Baselga et :11. “Phase 11 Study ofWeekly Intravenous Recombinant
`Human izcrl Anti-p185HER' Monoclonal Antibody in Patients \Vtth
`HERL’ncii-OverexprcssingMetnsuitic Breast Cancer“ .1. CI in. Oncol.
`14(1): 737-744 (Mar 19%)
`l-ltnrvtninrl Anti-1117.112 Amihody
`Hanelgn et al.. “Recombinant
`(llerccptin) l-‘nclwtcc: the Antilumot Activity of Paclitaxcl and
`Doxontbicin against HE Rlltrcu Overcxpessing Human Breast Can-
`cerXenograflt" Cancer Reticuch 58: 2825-1831 (1998).
`Benz ct 111.. “Estrogen-dependent, tamoxifen-resistant unnorigcnic
`growth of MCF-7 cells trusfected with liER2/tteu" Breast Cancer
`Research & Tmtment 24(2):85-95 (1992)
`Brodowi cz ct al., "Sinetc-agent gemcitabinc as second- and third-tine
`treatment in metastatic breast cancer" The Breast 9: 338-3112, (2000).
`Bmcggcmcicr. R.. “Arornatnac. nmmntasc inhibitors. and brcaat can-
`cer” American Journal of Therapeutics 8(5): 333-)“. (Sop-Oct.
`2001).
`Brutsky et al.. “Phase 11 study ofgernc itrrhine((‘rem) and trustuzumah
`(T) combinmion therapy in first. line metastatic breast cancer (MISC)
`patients (pts) with HERZ overexpression" Joumal ol'Clinical Oncol-
`ogy (Abstract No. 10591) 24(188‘) (Jun. 20. 2006).
`Bunnetal.,“13xprossion of l tor-22mm in human lung canccrccll lines
`by inunrtnohistochemislry and fluorescence in siltr hybridization ltlltl
`its relationship to in vitro cytotoxicity by irastuzumab and chemo-
`therapeutic agents” Clinical Cancer Research 7( 10):.121‘3-1250 (Oct
`20011.
`Brian etnl.. "HER2!nett expression and effects ol'HERCEPTIN alone
`and in combination with cytotoxic agents in lung cancer" Proceed-
`ittgs of the Amer ican Association for Cancer Research (Abstract No.
`45711-11: 719. (Mar. 2000).
`Burris er al , "Phase II trial ol‘docctaxel and Herceptirr(R) as first- or
`second-line chemotherapy for women with metastatic breast cancer
`whom.-
`lurnoiirs m-‘crcxptcas: lllflll” European Journal of ('nncct‘
`(Altsltttct No. 12'”) 35(4); H.122 (Sop 1999).
`litmliu c1 .11.. “.r\it:i.\lirr/rrlc. :1 )mtcrtl :ttul scluliw :iioinntasc ittltibi-
`tut.
`\L‘lbll:
`ritc'gcsttul
`.‘tcclirlt:
`itt
`txrsttttcrturviusrtl wriittcti with
`rulvn ncul lllt‘fls‘l utncct: lk'hlllh irl'uvcn row analysie ol‘lwri plats: III
`trials" Journal 011 linical ( Incology 111(7). 2000-3011 (Jul 1900)
`llrr/tlnr cl
`:rl.. “t-‘zirtrrmrlc Ill 1
`(t ‘( 18-10910.“ \ circuit irregcsttul
`itcclzilc trcntiitcrn of Imstiircrinixirisnl paticritx wrth irictiixlulic Itiensl
`carcinoma: results orlwo truirlotitr/cil tlotiblc lilinrl coritr‘rillcrl ntrrlti
`institutional lii;i|ir”(':tiiccr 717(12): 251).1-25|3.(ltiit. 15. 1096).
`(‘rrrririrhacl ct
`.11.. "Atlvancwl litcnsl cancer: :1 phase II trial with
`(:r‘uicilnhinr'" Journal an Iitticiil t inn-Inlay I 1(1 ll:’7‘il-.‘. i Mi (Nov
`tout.
`
`Carmichael ct :il.. “Advancul breast cancer: itivcstigatiunal role 01'
`gerncitabine" European Journal of CanCor .13(Siippl. ”$17-$30
`(Jan 1997)
`Carter et al.. "Humanizntion of an Anti-p185HbR2 Antibody for
`Human Cancer Therapy" Proc Natl. Acad. Sci. USA 89(10):-l285-
`4289 (May 1992).
`(‘hristodoulou ct 111.. “Combination ol'tntslucuinab and neiircitubinc
`as salvage treatment in metastatic breast cancer: The experience of
`the Hellenic Cooperative Oncology Group (lleCOG)” (Poster pre-
`sented at the 39th Annual ASCO Meeting held in Chicago. lllinois;
`May Ill-hut. 3. 9.003)
`Christodoulou ct 111.. "Gcmcitabinc and trastuzumab combination a:
`salvage treatment in patients with HER 2-posilive metastatic breast
`cancer" Proc Am Soc (flin nncnl (Abstract No. 166) 72:42 (2003).
`Clemons et
`.11.. "Review of recent
`trials of chemotherapy for
`advanced breast cancer: studies excluding taxrules" European Journal
`ol'Cnncer 33(13):2l7l-2 182 (Nov. 1997).
`"A concerted attack on cancer" Scrip Magazine 2617(Rcvicw issue
`2000):68-70 (Feb 14. 2001).
`D'Souza and Taylor-Papadimitrioti.. "Ovcrexpression of I-ZRBB) in
`Hurmn Mammary Epithelial (‘ells Signals inhibition of 'lrnmcrip-
`tion of the E-Cadherin Gene” Proc. Natl. Acad. Sci. USA
`9 l(lS):7202-7206. (1994).
`Dati ct al.. “Inhibition ofc—crbB-2 oncogene e‘tprcssion by estrogen:
`in human breast cancer cells” Oncogene 5(7):]001-1006(Jul. 1990‘).
`Davidson. N . “Single-agent pnclitaxel at first relapse following adju-
`vnnt chemotherapy for brunt cancer“ Seminars in Oncology 2205
`Suppl 14):2-0 (Dec. 1995)
`De Santes et al.._ “Radiolabeletl Antibody'largeting ol'tlie HER-Zlneu
`Oncoprolcin” Cancer Research 52: 1916-1923(1992).
`Di Flore at 1.1.. “crb13-2 ls aPotcnt Oncogene When Overcxprcssed in
`NIH-8T3 Celia" Science 237(481 1): 178-182. tJul. 10. 1987).
`Dickman. Sn “Antibodies stage :1 comeback in cancer treatment”
`Science 1806367): I ISM-11277. (199$).
`Drebin et al., “Down-Modulation of an Oncogene Protein Product
`and Reversion of the Transformed Phenotype by Monoclonal Anti-
`bodies” Cc]141(3l: 695-706. (1985).
`Drebin et .1. “Inhibition of Tumor Growth by a Monoclonal Anti-
`body Reactive thh an Oncogene-Encoded Tumor Antigen" Proc.
`Natl. Acad. Sci. 83: 9119-9133. (1986).
`Drebin et at, “Monoclonal Antibodies Reactive With Distinct
`Domains of the neu Oncogene-Enema p185 Molecde Exert Syn-
`ergistic Anti-Tm Efi‘ccts In V'rvo" Oncogene 2:273-2‘17. ( I988).
`Drebinetal.. ‘MonoclonalAntibodies Specific for thencu Oncogene
`Product Directly Mediate Anti-tumor BIIects In Vivo“ Oncogene
`2(4):.387-394 (1988).
`"equivocal" The American Heritage- Dictionary of the English Lan-
`guage (Definition found on http:.’.-’www.crerloreferencecom/enlry.‘
`4085073) (20031).
`"roman (lctmzolc tablets)" Physicians' Desk Rcfcrcncc (website
`version of product information) pp. 1-13. (2003).
`Fondly. BM. et al.. “Characterization of Murine Monoclonal Anti-
`bodies Reactive to Either the Human Epidermal Growth Factor
`Receptor or HEKL'neu Gene Predict" Cancer Resezuch 50: 1550-
`1558, ([990).
`Fleiss, JL Statistical Methods for Rates and Proportions. 2"”cdition.
`Nev/York. VY: Wiley pp. 13-17. (1981).
`Fornier el al. "Tntstuzuimb in combination with chemotherapy for
`the-treatment ofmelnstittic brcnxt cancer“ Seminars in Oncology 27(6
`Suppl ll)'RX-'15(l)cc 200(1)
`.‘i‘lkly oflrcrtwiinliMc'
`(iztlzctuciur cl
`:tl.. “A mruloirtiscrl phnsc ll
`cisplirlitt iilortc and “uh Ilcrccptiii in paliciits with Ill-.Rl-positiw
`tiorr-stiuill cell lung cancer (NS('1.(')" Il’oalct Io lit: irresctitcrl .‘rI tlrc
`21101 |i( '( 0 Howling).
`I‘DR". (300(1).
`('rcrtvsii'rpmrr‘italtiric llt'l ). "l’iortrict lnliiiitcition
`(innit-11 ct itl. "( linicirl activity 01' pctltmiinith (rhuMitll _’| 4) in
`irrlvrrrtccrl. rcl‘t'nctory or tccuircnl owiriitn cancer ((11 'I. and tho rule I“
`llliR.) activation Minus" .luirnal ol' ('lintcril Oncology [Abstract
`35051 r10“) Ihr: list
`\ttnttal Mcclinii ol' \S(‘(l) ZitlfiS'). «107$.
`(2005 r.
`111.. “('ruttmrisrm rtl' ntrlinrrgiopmic activities using
`cl
`(imnt
`pitclilitxcl ('Inxollantl thwctiixcl ('Itrxotcrc)“ Intuitalir-riiil .ltllllllill (if
`('zinccr “Ht 1 )' I? 1-13'). (2003)
`
`AMGKAN0297762'7
`
`

`

`US 8,309,087 B2
`Page 4
`
`Green cl u|.. "Preclinical Emlunlion of W'R-151327; Au Orally
`Active Chemotherapy Protector” Cancer Research 54(1):73X-74l
`(Feb. 1, 1994)
`Grem et «1.. “A phase II evaluation of combination chemotherapy
`plus uninoglutcthrmidc in women with metastatic orrccurrcnt breast
`carcinoma. An Eastern Cooperative Oncology Group Pilot Study"
`American Journal ol'Clinical Oncology 1 1(5); 528-534. (Oct. 1988).
`Guy et at, "Expression of the netr Protooncogene in the Mammary
`Epithelium of'l'ransgcnic Mice lntltrces Metastatic Disease.“ Proc.
`Natl. Acad. Sci USA 89(22): 10578-10582. (1992).
`Hamilton rind Piccnn. " I he contribution ofrnolccular markers to the
`prediction of rcrponsc in the treatment of breast cancer: a review of
`the literature on HER-2. p53 and BCL-Z" Annals of Oncology
`I l(6):647-663 (Jun. 2000).
`Hancock et al.. “A Monoclonal Antibody Against the c-erbH-l Pro-
`tein Enhanccs the Cytotoxicity ol' cis—Diammincdichloroplatintun
`Against Human Breast and Ovarian Tumor Cell Lines" Carla?
`Research 51:45754580. (Sep. 1. 1991).
`Hansen. 11.. “(icnrcitubinc
`a review" Armuls Q/‘Orrmlogv (Abstract
`#058 from the 9th NC l—EORTC Symposium on New Dnlgs in
`Cancer Therapy held in Amserdam on Mar. 11-15. 1996).
`Harwerth et al.. “Monoclonal Antibodies Against the Extracellular
`Domain ofthe erbB-2 Receptor Function as Partial Ligand Agonists"
`Journal of Biological Chemistry 267(21): 15160-15167. (Jul. 25.
`I992).
`“Hutu-pun ('1‘rastummab)" Product Information (2000)
`l-lcrzig nndHerrig. “Medical Oncology" (website link. ht‘tp'r'uvww
`guatitysurgical org/'Chnptcr'km'l‘l htrn) pp. 1-1 I, (21116).
`Hirsch et a1 . “Preclinical studies of gemcitabine and trastuzumab in
`breast. and lung cancer cell lines" Clinical Brimsl Cancer (abstract
`only) 3(Suppl I); 12-16 (May 20021.
`Hudziul; a :11, “Increased Expression of the Putative Growth Factor
`Receptor pittSsHR‘ Causes 'l‘mnsl'onmtion and Tutmrigenesis of
`NH 3T} Cells” Prnr. Natl. Arad. SN. USA 34(20): 7159-7163.
`(1987).
`Hudziak at 9.1.. “[11855er Monoclonal Antibody Has Antiproliferative
`Effects In Vitro and Sensitizcs Human Breast Tumor Cells to Tumor
`Necrosis Factor" Molecular & Cellular Biology 9(3). 1165-1172,
`(1989)
`Hymn and Stern. "The BiologyoferbHJ/neiuHER-Z and Its Role in
`Cancer” Uiochlrriica at Biophysics- Ada 1198(2-3): 165-184. (Dec.
`30. I994)
`llgert ct al.. “Characterization ol‘anti-Hl-IRQ antibodies which inhibit
`the growth ot‘brcast tumor cells in vitro" Proceedings ofthe Ameri-
`can Association for Cancer Research (abstract 1/3209) 37:470 (Mar.
`I996).
`Kasprzyk at 1]., "Therapy of an Animal Model of Human Gastric
`Cancer Using a Combination ot'Anti-crbB-Z Monoclonal Antibod-
`ics” Cancer Research 52(10): 2771-2776. (1992).
`KnuI‘rmnn or at, “I’xcmcstano is superior to mega-mo] acctnto alter
`trumxil'en failure irt postmenopausal women with udranuetl brunt
`cancer: Results ofa phase III randomized double-blind trial“ Journal
`ofrTlinir'aI Omvrlogy lRt'7):l30|7-I4I I (Apr 2000).
`Kay: at 511., “Phat: II trials of docetaxcl (‘I'axotcrc) in advanced
`ovarian cancer
`an updated oven'iew" European Journal of Canccr
`33(13): 2167-2170. (Nov. 1997).
`Kim ml at. "Both the qtilolx: specificity and isotypc are important in
`the antituinor etTuct of monoclonal antibodies against Her-2mm
`antigen" lrrlernatimml .hmrrml rifti'rrrrrrr lOZ(4):4ZX-434. (200).)
`Klijn nt .11 . "l‘linical him-st cancer. nc‘w developments in selection
`and endocrine licntnimtl 01' patients" ..’uurnal Lf/ Sltr'uitl [lion/Ir
`
`rrrirlly .Q .lIIr/t'r'II/m' Bin/0'4} ‘13( l-
`: 2| 1-321. (10931.
`Kolltfltyct.rl.. "New ill 1123 It: lirunst cancer therapy; ('tnrcnl position
`and
`l‘trltirc
`[matte-clots"
`(it‘rrru'idtguiai Ir-(itlnrr'lsllr'lllir‘llr'
`Ruth/Witt!!! tlmglisli language :ilrstmct onlyt ‘Tt3t: iii-til (I007)
`Kong-(n): t-t :il . ”'I hourpctttit'
`.‘rtlvnnlngu at chemotherapy drugs in
`combination with llliltt'lzl’l l.\ 'tgzrrnsl human breast cancer calls
`with
`Ill-.R-Ierill
`ttVClIJNPIL'SNIt‘II"
`Ilr'r'rrxl
`('rult'r'r New Ii't'rll
`l.\ltsltatt Vt) 467) 57 IN. t1"‘i‘)).
`KI‘Ii‘l.‘ ct .r|.. “|)illcicrrti:rl (in-“1h Inliilntir-n ol'llilnran ('arcinorm
`('t'lls l vposnl In \vltrnticlnnal In Vilm Antilmtlit‘: Itircduil against
`thc Fx‘lntu‘lltilni Domain \‘|
`tho 11171293171111“? l'rolnunt‘trgonc“
`(Abstract "I 7(1) 10(3) 5‘)\(l‘1')ll).
`
`Krona: et al.. “Reguluion of Phosphorylaiion oftlrc c-crbB-.‘11ER2
`Gene Product by a Monoclonal Antibody land Senna Growth Fac-
`tods‘t in Hturutn Mammary Carcinoma Cells" Molecular & Cellular
`Biology 11(2): 979-985, (1991).
`Kunisuc ct nl., "Anti-HERZ antibody enhances the growth inhibitory
`efimt of anti-oestrogen on breast cancer cells expressing both
`oestrogen receptors turd HERZ" British Journal of Cancer 82(1).
`46-51. (2000).
`Icwis et at. “Differential Responses of Human Tumor Cell Lines to
`Anti—p185"ihR' Monoclonal Antibodies" Cancer
`Immunol.
`Immunothcr. .17: 255-26] (1993).
`Lewis et at. "Growth Regulation of Human Breast and Ovarian
`Tumor Cells by Ilercgulin: Evidence for the Requirement ol‘ErbBZ
`as a Critical Component in Mediating Hercgulin Responsiveness"
`('nncchesearch 56-. 1457-1465, (Mar. 15, 1996).
`Llomban ct 31., “Biweekly gemcitabine and paclitaxel in advanccd
`breast cancer. Phase II trial and predictive value of HER: extracel-
`lulardomain(ECD)" European Journal ot'(‘nncer (Abstract No 390)
`36(Suppl 5): $121-$122. (Sop. 2000),
`Lottrisch and Piccan. “an cancer new aspects or adjuvant hor-
`monal therapy" Annals of Oncology lltSunle): tit-2542000),
`Maier et al. "Requirements for the Intemalizntion of a Murine
`Monoclonal Antibody Directed against the HER-2/lcu Gene Product
`c-crbB-Z" Cancer Research 51(19): 5361-5369. (1991).
`Marty ct al.. "kantlomized Phase“ Trial ofthe Efficacy and Saficyof
`Trastummtib Corrbincd with Doceurxet in Patients with Human Epi-
`dermal Grovnh Factor Receptor 2-l’osirivc Metastatic Breast Cancer
`AdministeredAs First-Lino‘lrenuncnt"JoumalofL‘tinical Oncology
`23(19): 4265-4274 (Jul. l, 2005).
`Masai ct 111.. “Growth Inhibition ol'Hurnan Tumor Cells in Athymic
`Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Anti~
`bodies“ Cancer Research 44(3); 1002-1007. (1984).
`Masuka at 31.. "A marine Monoclonal Antibody 'l'hat Recognizes an
`Extracellular Domain of the Human c-crbR-Z Piotooncngcnc Prod-
`uct." Jpn J. Cancer 11:3.80; 10-14, (1989).
`Mch et al., "c-erbB—2 Oncoprotein Expression in Primary Human
`Tumors" Cancer 65(1):88-92. (1990)
`McKenzie ct Il.. “Generation and Characterization of Monoclonal
`Antibodies Specific for the Human ncu Oncogene Product. p185“
`Oncogene 4543-548 ([089)
`Mendelsohn ct IL. “Receptor Blockade and Chemotherapy A New
`Approach to Combination Cancer Therapy." Annals of Oncoloy
`(abstract W0) 7(Suppl. 1): 22. (1996).
`Merlin et al.. “In vino comparative evaluation of Irastuzumalr
`(llciccplinkombined with paclitwtcl (Taxolj or dowlaxel (Tumors)
`in HERZ-arpressing human breast cancer cell
`lines" Annals of
`Oncology 13(11): 1743-17-18 (Nov.2002).
`Miller et al.. "Gemcitabine. paclitaxel. and trastuzumab in metastatic
`breast cancer" Oncology 15 (2 Supp 3): 3840. (Feb. 2001).
`Miller ct a1, “th 11 study of gctncitabinc, paclitmcl and
`uasluzurnab in metastatic breast cancer; a Hoosier Oncology Group
`trial“ (Abstract #437. Presented at
`the 2002 SABCS meeting.)
`(2002).
`Mizukami et 31., “Iifl‘ects ot'tamoxifcn. mcdroxypi ogesterone acetate
`and estradiol on tumor growth and oncogene expression in MCF-7
`breast cancer cell
`line transplanted into nude mice" Anticancer
`Research I
`|(fl_): 1313-1338. (May-Jun. 19911.
`Mosconi at 111.. "Combination therapy with gemcitabirte in non—small
`cell lung cancer" European Journal Mfume-r 13(Suppl
`I): S lot-SI 7,
`(Ian 1007)
`Myers \:l
`.11.. “Biological tent-m ol' Monoclonal Antiiwcplor Anti-
`bodies Reactive “ilh nun (Inn-gum: Product. |Il$5nctl" Mclhtrtls: in
`l.rt'/.yrtro|o)ry tony-7.290 ( I'M l ).
`Nnmmltz cl :tl . "Results ul‘Z open Irrlicl itnrlliccntic plrasc 1| pilot
`studies with llctccptin in corirliiimtion with IlttCL‘Ir'L\C‘ .k platinum
`stills (t'is' or ( .‘trboplaltnt (I('ll) rrs tltcinliy l'or' mluirtcol Inc-mt
`cancer in women \\'l|il1111110”:OVL‘I'CNPICSSIIIgllIG Ill-IR_‘~ricu”l~.ur
`I
`('nnccd Aim (105] ,i7r’Kup (\):SI‘X) (Jlllll)
`Nulrlroltzct nl . “Rumba nl‘lmr uan-lillrcl irnilticcntrt; pilot phase II
`trials “'tlll llcrccptiit in continuation with rl-rcctaxcl and platinum
`salts (('i~< or (':trlrnpl:rlirr) (It'll) .‘IS Ilit'rnpy l‘or minimal lrrcnsl
`t'nnct-r in women in t‘rt‘a’pwssing l I ER)" l'trmsl C it our Rt‘smrt'li r‘ll‘.t1
`lN—‘tllllL‘lll (Abstract ’ .127) M( I t: 82 (2001:)
`
`AMGKAN02977628
`
`

`

`US 8,309,087 Bl
`Page 5
`
`Nagoumcy ct 311.. “Trastuztuturlt ('HERClEl’TlN) enhancement of
`cytotoxic tints activity in human tumor primary cultures". Breast
`Cancer ltcs treat (Abstract No. 47S) 57: Ho, (1999).
`Nallani et a1.. "Difl‘erences in the induction ofeytochrome P450 3A4
`by taxanc anticancer drugs, doeetaxel and pnclitaxol. assessed
`employing primary human hepatocytes" Cancer Cherrrotlrcrapy &
`Pharmacology 54: 219-229. (Sep. 2004).
`Nelson and Fry. "Inhibition of ERBR family receptors bth-lm}
`enhancesthe cytotoXicity ofgemcitabine via modulation ot‘A K'l‘and
`map kinasex" Proceedings 01' the American Association for Cancer
`Research (Alistmct No.
`|$"1_‘l)4 I: 241, (Mar. 3000).
`Nogueraa at a] , “Pilot study ofgernc itahinc (G) plus trastuzurnabd I)
`in metastatic breast cancer patients with orb-2 overexpression previ-
`ously trained with anthracyclincs (A) and taxartes (1)" European
`Journal 01'. Cancer (Abstract No. 416)4(3urp1_t2169(Mai. 2006).
`Norton, L. "Evo ving Concepts in the Systemic Drug Therapy 01'
`Breast Cancer" Seminars in Oncology 24 (4 Suppl 10): 510-3-510-
`10 (Aug. 1997)
`()‘SiuIUgltncssy at at. “Phase 11 Sllltly of lraslomurab plus
`gemcitabinein chemothetnm'pretreated patients with metastatic
`breast cancer" Clinical Breast Cancer 5(2): 142-147, (Jun. 2004).
`U 'Shaugltnessy et at ., "Phase 11 trial of gemeitabine plus trastuztunab
`in metastatic breast cancer patients previously treated with chemo-
`therapy preliminary results" Clinical Breast Cancer (abstract only)
`3(Suppl I): 17-10.t‘_May 2002).
`Peacock et at. “Phase 11 trial 01' gemcitahine plus traslu'lumlb in
`minimally pretreated HERZ overexprcssing metastatic breast can-
`cer" Journal ot'CtinicaI Oncology (Abstract No. 704)23(1(\5 Part] of
`11): 545(Jun 1.2005).
`chram ct 11.. “Effect of erbB-Z (HER-Z’aou) overexprcssion on
`chemotherapeutic drug sensitivity in hum an breast and ovarian can-
`cer cells“ Proceedings of the American Association for Cancer
`Research (Abstract No. 152).“: 26 (Mar. 1993).
`Peyton at at . “Inhibitory effects of combinations of HER-Mien
`antibody and chemotherapeutic agents used for treatment ot’human
`breast cancers" Oncogene 18: 2241-1251. (1999).
`Perez and Hartrmnn, “I‘aclitaxcl and carboplatin for advanced breast
`cancer" Seminars in Oncology 23(5 Suppl 11).41‘15 (Oct. 1996).
`Piccart and Kaufmann. "Introduction“ European Journal of Cancer
`~t7 (Suppl. I): 81—32 (Jan. 2.001)-
`Piccan et al.. "Hutu; a predictive factor ready to use in the daily
`management ot‘breast cancer patients?" European Journal ot'Canoer
`36(14):l755-l761 (Sep. 2000).
`Heart. M, “Closing remarks and treatment guidelines" European
`Jorunal ofCarrcet 37(Suppl. 1)‘ 830-833 (2001).
`Pictras et a1 . “Antibody to HER-yneu Receptor Blocks DNA Repair
`Alter Cisplatin in Human Breast and Ovarian Cancer Cells"
`Oncogene 9: 1829—1838 (1994).
`Pictras ct al.. “HER-2 tyrosine kinnse pathway targets estrogen recep-
`tor" and promotes honnouc-indcpcndent growth in human breast can-
`cer cells" Orwgcnc 10(12): 2435-2446 (1995).
`Pictras er al.. "Hercgutin promotes growth of human breast cancer
`cells with HER-2 (erh Bl) receptors" Proceedings of the American
`Association for Cancer Research (Abstract No. 573) 34: 96 (Mar.
`1993)
`Reefstty et 211.. “Phase 11 Trial ofDocetaxcl and tletceptin as First- or
`Second-Line Chemotherapy for Women with Metastatic Breast (Zan-
`ccr Whose Tumors Ovorexpross 1113112" Proceedings of ASCO
`(Abstract r1523) r 1999)
`ltavdin and t ‘hamncse. "'1 ho c-cth-2 prom-oncogene as .1 prognos-
`tic and predictive marker in tunnel cancer: .1 paradigm for tho tlcvul
`utmtcnt ol't-tltcr trurctontnlcutlar tntttkcts
`:I lL‘t'1c\\" (icut: 159(1):
`19-31(10‘“).
`Itcutl cl :i|.. "lltrrurotrttl rrtotiulntimt ol‘ IIIiR-Z nut pttrtrroncrgulc
`urcs.‘
`Igor ribonucleic (iii and pla‘fi protein corrosion in hunuur
`
`
`lrrrast L'zult‘t'l'ucll lines" t'mccr Research 50( 13 I: 3947-305 1.1 1990).
`Robert ct
`:rl.. “Phase III cornpnratiw study vl ”tutu/numb :mrl
`pitclrlaxcl with and without cttrturplatin in patients with ”lithium
`rmsitnc :ulwrucoil lucasl \ililbk‘l". (Abstract 1/15. Presented at
`the
`.7003 5.41108 rrrcctittg)
`RI‘tlL‘L‘L or
`.11.. “tumult-rims hrlwcuu growth thclot receptors :rml
`t'rlrtt‘spttl‘ltllng monoclonal antibodies in human tumors" .1 t'ulltrlnr
`Hint-horn “14); 315-120. 1 m7)
`
`Safian el '41.. “Herceptin anti getnrilabinc for metastatic pancreatic
`cancers that overexpress HER-yaw” Proc Am Soc. Clin. Oncol.
`(Abstract No. 517) 20:130/\ (2001).
`Santen and Harvey. “Use of aromatase inhibitors in breast carci-
`noma” Endocrine-Related Cancer 6(1): 75-92. (1999).
`bantp et at, "Characterization of an Anti-PISSHHU Monoclonal
`Antibody that Stimulates Receptor Function and lnhibiis'i‘umor Cell
`Growth" Growth Regulation 1: 72-82 (1991).
`Schlotn. .l., "Monoclonal Antibodies